|
|
||||||||
J Thorac Cardiovasc Surg 2000;119:477-487
© 2000 Mosby, Inc.
CARDIOTHORACIC TRANSPLANTATION |
From the Department of General and Thoracic Surgerya and the Institute for Pathology,b University of Giessen, Giessen, Germany.
Address for reprints: Helmut Grimm, MD, PhD, Department of General and Thoracic Surgery, University of Giessen, Rudolf-Buchheim-Strasse 7, D-35392 Giessen, Germany (E-mail: helmut.grimm{at}chiru.med.uni-giessen.de ).
Introduction: Whereas the involvement of elicited xenoantibodies in delayed xenograft rejection is currently being substantiated, this study focuses on the role of the preformed fraction of xenoantibodies.
Methods: To check the influence of the latter, we combined pretransplant complement inactivation (cobra venom factor) and antibody reduction (plasmapheresis) in a guinea pigtorat heart transplant model.
Results: Antibody reduction on plasmapheresis before xenografting did not prolong delayed xenorejection in decomplemented rats, although the immunohistologic pattern lacked the immunoglobulin deposits along endothelial walls found in xenografts of merely decomplemented recipients. Astonishingly, plasmapheresis, if carried out 2 days before transplantation, almost tripled xenograft survival, although preformed antibody levels were completely restored and even rebounding at the time of grafting. The pattern and number of infiltrating cells did not differ in dependence of the timing of plasmapheresis nor did the proliferative response of lymphocytes in the mixed lymphocyte reaction differ. However, plasmapheresis led to a retarded decrease of the mononuclear cell tumor necrosis factor
secretory potential, which correlated well with a diminished immunohistologic staining of tumor necrosis factor
secreted by graft-infiltrating mononuclear cells.
Conclusion: These findings argue against a pivotal role of preformed xenoantibodies in the pathomechanistic process of delayed xenograft rejection and challenge the therapeutic strategy to reduce preformed xenoantibody levels before xenotransplantation in complement-inactivated recipients.
This article has been cited by other articles:
![]() |
T. Hasegawa, K. Okada, Y. Takano, Y. Hiraishi, and Y. Okita Autologous fibrin-coated small-caliber vascular prostheses improve antithrombogenicity by reducing immunologic response J. Thorac. Cardiovasc. Surg., May 1, 2007; 133(5): 1268 - 1276. [Abstract] [Full Text] [PDF] |
||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| ANN THORAC SURG | ASIAN CARDIOVASC THORAC ANN | EUR J CARDIOTHORAC SURG |
| J THORAC CARDIOVASC SURG | ICVTS | ALL CTSNet JOURNALS |